Overview
MAV+ is a comprehensive support package tackling barriers to manufacturing and access to health products and technologies in Africa that is tightly aligned with African strategies and priorities.
The overall objective of MAV+ is to facilitate access to quality, safe, effective and affordable health products as outlined in the UN’s Sustainable Development Goal Target 3.8.
MAV+ is aligned with the EU’s Global Health Strategy and Global Gateway strategy as well as the Framework for Action from the Africa CDC’s Platform for Harmonized African Health Products Manufacturing, and it complements other Team Europe Initiatives working on health and social protection in Africa.
MAV+ is a comprehensive 360-degree initiative that focuses on three dimensions supply, demand and enabling environment; and is organised in 6 workstreams:
- industrial development, supply chains and private sector
- market shaping, demand and trade facilitation
- regulatory strengthening
- technology transfer and intellectual property management
- access to finance
- R&D, higher education and skills
More detailed information available on the Team Europe Initiative on manufacturing and access to vaccines, medicines and health technologies in Africa page.
Key information
- Global Gateway areas of partnerships
Health
- Type of initiative
Regional
- Geographical focus
Sub-Saharan Africa
- Countries
Ghana; Nigeria; Rwanda; Senegal; South Africa
- Team Europe members involved
Belgium; Netherlands; Spain; Sweden; France; EIB; Germany; Luxembourg; European Commission
- Initiative ID
IDI134-3; IDI134-4; IDI134-5; IDI134-6
Milestones
IDI134-3; IDI134-4
- Upgrade of the FDA biologics laboratory (clean room) to be operational in 2023 at Biological Safety level 3, Institutional development plans for the Ghanaian FDA to reach WHO maturity level 4 (for pharmacological vigilance it already reached level 4
- Disbursement of EIB loan
IDI134-5
- Start of negotiations for a Sustainable Investment Facilitation Agreement with Nigeria
Financing agreement signed
IDI134-6
- Launch and/or running of Educational programs
- Rwandan FDA reaches the maturity level 3 (WHO ranking)
- Official start of the Rwanda Bioeconomy Skills and Acceleration Centre (Q2 2024)
- Concept for sustainable operation of the laboratory (Q4 2024)
